NGD-4715 is an investigational compound developed for the treatment of Obesity. NGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.
- Mechanism
- Curator reviewed
NGD-4715 works as a small molecule antagonist at the melanin concentrating hormone receptor-1 (MCHR1). Neurogen’s obesity program has focused on blocking the melanin concentrating hormone receptor-1 (MCH1). Reported studies in rodents support MCH being an important mediator of caloric intake. Deletion of MCH or the MCH1 receptor gene resulted in lean animals, while over-production of MCH caused increased weight gain. Neurogen’s studies indicated that selectively blocking MCH1 was sufficient to achieve a significant reduction in food intake in a higher animal species.
- Primary indication
- Investigated for use/treatment in obesity.Curator reviewed
- Formula / weight
- C19H24BrN3O3 · 422.323 g/mol (avg)
- Also known as
- 1-(5-bromo-6-methoxypyridin-2-yl)-4-(3,4-dimethoxybenzyl)piperazine · 1-(5-bromo-6-methoxypyridin-2-yl)-4-[(3,4-dimethoxyphenyl)methyl]piperazine
- Code names
- NGD-4715
Resolves to
VAKYVNYLCIABRV-UHFFFAOYSA-NSMILESCOC1=C(OC)C=C(CN2CCN(CC2)C2=NC(OC)=C(Br)C=C2)C=C1What you can answer from here — as of April 02, 2025
Which drugs share a target with NGD-4715, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account